NCH is the First in Florida to Provide Pulsed Electric Field (PEF) Ablation

NCH continues to lead the way in medical innovation, becoming the first healthcare provider in the state to offer the groundbreaking Van Gogh Biopsy tool from Aquyre Biosciences. This advanced technology redefines traditional biopsy procedures, providing results in as little as two minutes and eliminating the need for time-consuming traditional lab-based analysis. The Van Gogh Biopsy technology is designed for use in assessing tissue during cancer diagnostics, and can rapidly identify cancer, immune and other cells. The tool leverages real-time optical imaging to evaluate tissue with exceptional precision, streamlining the diagnostic process and improving patient care. Unlike conventional methods that require tissue samples to be sent to a lab for analysis, the Van Gogh system provides instantaneous feedback, enabling physicians to make informed decisions on the spot. At NCH, we are committed to offering cutting-edge technology that enhances the patient experience, said Paul Hiltz, President and CEO of NCH. The Van Gogh Biopsy Tool aligns perfectly with our mission, allowing us to provide faster, more accurate diagnoses while reducing the stress and uncertainty for our patients. This innovative tool is particularly beneficial for patients undergoing evaluations for conditions where time is critical. By reducing the diagnostic process from days to mere minutes, the Van Gogh system empowers physicians to create immediate, tailored treatment plans. The addition of the Van Gogh Biopsy Tool underscores NCHs dedication to advancing healthcare quality and ensuring patients in Southwest Florida have access to the best and most efficient diagnostic tools available.

Named as One of Americas 50 Best Hospitals for 2025 by HealthgradesNaples Comprehensive Health (NCH) is proud to announce its recognition as one of Americas 50 Best Hospitals for 2025, according to newly released research by Healthgrades, the nations leading resource for information about doctors and hospitals. This prestigious accolade reflects NCHs unwavering commitment to delivering superior patient care, placing it in the top 1% of all U.S. hospitals for overall care excellence. In addition to this honor, NCH is currently the only hospital in the nation to achieve Healthgrades highest recognition in three critical areas: Cardiac Care, Orthopedic Surgery, and Overall Clinical Excellence. These achievements underscore NCHs dedication to setting and exceeding the highest standards of quality and innovation in healthcare. NCHs achievements are based exclusively on what matters most: patient outcomes. To determine the top hospitals for 2025, Healthgrades evaluated risk-adjusted mortality and complication rates for over 30 of the most common conditions and procedures at approximately 4,500 hospitals nationwide. Healthgrades annual analysis revealed significant performance gaps between the nations highest- and lowest-achieving hospitals, making it increasingly important to seek care at a top-rated facility. If all hospitals, as a group, performed similarly to NCH being named among Americas 50 Best, 173,516 lives could have been saved.  Five years ago, our vision was to become a top 50 healthcare system in the nation, said Paul Hiltz, President and CEO of NCH. Were proud to celebrate this accomplishment because of the tireless efforts of our physicians, nurses, and staff who prioritize excellence in every aspect of patient care. Our teams commitment to transforming quality and enhancing the patient experience helped us achieve this vision. Being recognized for superior outcomes in cardiac care, orthopedic surgery, and overall clinical excellence is a testament to the extraordinary teamwork and dedication of our organization. This achievement places NCH among the nations healthcare elite. Healthgrades 50 Best Hospitals designation is its highest achievement, recognizing institutions that consistently deliver superior clinical outcomes. NCHs exceptional performance in these areas reinforces its reputation as a trusted leader in healthcare, both in Florida and across the nation. As one of Americas 50 Best Hospitals, NCH is elevating the standard for quality care nationwide, said Brad Bowman, MD, chief medical officer and head of data science at Healthgrades. Healthgrades commends NCH for their leadership and ongoing commitment to providing the best possible care for all patients in Southwest Florida.  For more information about NCH and its award-winning services and care, please visit www.NCHmd.org.

Naples, FL., August 19, 2024   Naples Comprehensive Health (NCH) proudly announces that it has become the first healthcare facility in Southwest Florida to offer Drug-Coated Balloon (DCB) procedures at the Rooney Heart Institute. This cutting-edge intervention is now available to patients with cardiovascular conditions, particularly those experiencing in-stent restenosisa condition where arteries previously treated with stents become narrow again.The DCB procedures, powered by the latest technological advancements, utilize the high-tech agent DCB device developed by Boston Scientific. This innovative approach allows physicians at the Rooney Heart Institute to deliver targeted therapy directly to the affected arteries, minimizing the risk of recurrent narrowing and significantly improving patient outcomes.We are thrilled to bring this groundbreaking technology to our patients in Southwest Florida, said Adam Frank, MD, Interventional Cardiologist, NCH Rooney Heart Institute. The introduction of Drug-Coated Balloon procedures at NCH represents a major advancement in cardiovascular care, offering new hope to patients who have previously undergone stent placement and are now facing the challenge of in-stent restenosis.The DCB device developed by Boston Scientific works by delivering medication directly to the artery wall, which helps prevent scar tissue formation that can lead to restenosis. This approach offers a minimally invasive solution, reducing the need for repeat interventions and providing patients with a faster recovery time.By adopting this advanced technology, NCH continues to lead the way in providing innovative cardiovascular care in our region, said Robert J. Cubeddu, MD, President of the NCH Rooney Heart Institute. Our commitment to bringing the latest treatments to our patients is unwavering, and the introduction of DCB procedures is a testament to that dedication.The Rooney Heart Institute at NCH is renowned for its comprehensive cardiovascular care, offering a wide range of state-of-the-art treatments and nationally recognized procedures.  NCH received the highest rating of three stars from the Society of Thoracic Surgeons for CABG cardiac procedures; was named among the top 50 hospitals in the nation for cardiac care by Healthgrades; and ranked as #50 in the U.S. for Cardiac Services by Money. The addition of Drug-Coated Balloon procedures further enhances the institutes ability to provide cutting-edge care to patients with complex cardiovascular conditions.For more information about the Drug-Coated Balloon procedures or to schedule a consultation, please contact the NCH Rooney Heart Institute at 239-624-4200 or visit NCHmd.org.